Copyright
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Nov 16, 2022; 10(32): 11690-11701
Published online Nov 16, 2022. doi: 10.12998/wjcc.v10.i32.11690
Published online Nov 16, 2022. doi: 10.12998/wjcc.v10.i32.11690
Emerging potential of ubiquitin-specific proteases and ubiquitin-specific proteases inhibitors in breast cancer treatment
Mei-Ling Huang, Nan-Lin Li, Department of Thyroid, Breast and Vascular Surgery, Xijing Hospital, The Fourth Military Medical University, Xi’an 710032, Shaanxi Province, China
Guang-Tai Shen, Department of Breast Surgery, Xing'an League People's Hospital, Ulanhot 137400, Inner Mongolia Autonomous Region, China
Author contributions: Shen GT and Li NL designed the research study and guide the writing; Huang ML performed the research, analyzed the data and wrote the manuscript; Shen GT guide the revision of the manuscript; all authors have read and approve the final manuscript. Huang ML and Shen GT contributed equally to this work.
Supported by the National Natural Science Foundation of China , No. 81472598 ; and Project of Xijing Hospital , No. XJZT18MJ30 .
Conflict-of-interest statement: All the authors declare that they do not have any conflict of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Nan-Lin Li, PhD, Professor, Department of Thyroid, Breast and Vascular Surgery, Xijing Hospital, The Fourth Military Medical University, No. 127 Changle West Road, Xi’an 710032, Shaanxi Province, China. linanlingo@126.com
Received: June 30, 2022
Peer-review started: June 30, 2022
First decision: August 21, 2022
Revised: August 30, 2022
Accepted: October 17, 2022
Article in press: October 17, 2022
Published online: November 16, 2022
Processing time: 131 Days and 5 Hours
Peer-review started: June 30, 2022
First decision: August 21, 2022
Revised: August 30, 2022
Accepted: October 17, 2022
Article in press: October 17, 2022
Published online: November 16, 2022
Processing time: 131 Days and 5 Hours
Core Tip
Core Tip: Ubiquitin-specific proteases (USPs) are emerging as potential therapeutic targets in many diseases. In breast cancer, several USPs were overexpressed. In this study, we summarize the involvement of USPs in breast cancer and the development of USP inhibitors, providing more reference to discover potent and selective clinical candidates.